Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance

Pharmacogenomics

Volumn 6, Issue 7, 2005, Pages 721-730

  Chen, Li Yan ^a,b   Huang, Jian ^b   Zhang, Xin Ping ^c   Qiao, Ping ^b   Zhang, Wen ^b   Yang, Ning Min ^d   Liu, Hong Jing ^c   Geng, Yong Yao ^b   Qiu, Jian Ming ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b Shenzhen YiShengTang Biology Medicine Ltd   (China)

^c Hangzhou Sixth Hospital   (China)

^d Hangzhou Zhiyuan Institute of Medical Diagnostics   (China)

Author keywords

Clinical evaluation; Hepatitis B virus; Hepatitis B virus DNA polymerase; Lamivudine resistance; Oligonucleotide microarray

Indexed keywords

DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CODON; CONTROLLED STUDY; DNA MICROARRAY; DNA SEQUENCE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; VIRUS MUTANT;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 26944494077     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.7.721     Document Type: Article

References (18)

1. Zoulim F: Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res. 44, 1-30 (1999).
2. Chayama K, Suzuki Y, Kobayashi M et al.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-1716 (1998).
3. Lai CL, Liaw YF, Leung NWY et al.: Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters. Hepatology 26, 259A (1997).
4. Niester HGM, Honkoop P, Haagsma EB et al.: Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177, 1382-1385 (1998).
5. Guo S, Fandian Z, Tiancai W: The research progress of the new drug lamivudine against HBV. The New Drug Magazine of China 10(2), 96-99 (2001).
6. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-717 (1996).
7. Ling R, Mutimer D, Ahmed M: Selection of mutation in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711-713 (1996).
8. Allen MI, Deslauriers M, Andrews CW et al.: Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatology 27(6), 1670-1677 (1998).
9. Satsuki K, Kazunori S, Hiroshi S, Kyuichi T, Michio S: Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatology 17, 31-42 (2000).
10. Stuyver L, Geyt CV, Gendt SD et al.: Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38(2), 702-707 (2000).
11. Lok ASF, Zoulim F, Locarnin S et al.: Monitoring drug resistance in chronic hepatitis B virus(HBV)-infected patients during lamivudine therapy: evaluation o performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40(10), 3729-3734 (2002).
12. Stuyver L, Van Geyt C, De Gendt S et al.: Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38(2), 702-707 (2000).
13. Osiowy C, Giles E: Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J. Clin. Microbiol. 41(12), 5473-5477 (2003).
14. Kazuaki C, Yoshiyuki S, Masahiro K et al.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-1716 (1998).
15. Hacia J: Resequencing and mutational analysis using oligonucleotide microarrays. Nature Genet. 21 (Suppl. 1), 42-47 (1999).
16. Cheng ZB, Gao W, Guan W, Wang SQ: The preparation and characteristic analyse of the HBV drug-resistant oligonucleotide microarray. The Magazine Of The Liver Illness of China 11(1), 46-47 (2003).
17. Li ZG, Chen LY, Huang J et al.: Quantification of the relative levels of wild type and lamivudine-resistant mutant virus in serum of HBV infected patients using microarray. J. Viral Hepatitis 12(2), 168-175 (2005).
18. Sun J, Wang Z, Ma S et al.: Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J. Med. Virol. 75(3), 391-398 (2005).